new oral insulin

November 21, 2008

Generex Launches Oral Insulin for Diabetes Management

Generex announces a partnership with a company to promote their oral insulin

with more than a 1000 person sales force in India.

Generex Biotechnology Corporation the leader in drug delivery for metabolic

diseases through the inner lining of the mouth, and Shreya Life Sciences

Pvt.

Ltd., the Company's importation, marketing and distribution licensee in

India and the fourth largest marketer of insulin in India, jointly announced

last

Friday, the launch of commercial retail sales of Generex Oral-lyn in

India. Generex Oral-lyn is approved in India for the treatment of adults and

children

with Type 1 and Type 2 diabetes and will be marketed and sold in India under

the brand name " Oral-Recosulin " .

Shreya will offer the product through its sales force of more than 1,000

people and will implement a continuing medical education program to

introduce

the product to endocrinologists, diabetologists and physicians in India and

expects that the product will eventually be available in more than 2,500

pharmacies

in the country.

The launch of Oral-Recosulin, which offers a simple, convenient, fast,

effective, flexible, familiar and pain-free alternative to prandial

injections of

insulin, coincides with the United Nations' World Diabetes Day, celebrated

annually on November 14. The product is expected to be widely available for

retail purchase in India before the end of the month.

" It is with great anticipation and enthusiasm that we launch this innovative

new product for the Indian diabetes market. Diabetes is reaching epidemic

proportions in India, with over 40.8 million diagnosed patients and an

estimated 35.9 million additional people with pre-diabetic conditions which,

if

not properly treated and managed, could lead to full-blown diabetes, " said

Sujit Kumar Singh, the Chairman & Managing Director of Shreya. " Early

intervention

with insulin therapy could delay the onset and progression of diabetes and

its numerous complications. Generex Oral-lyn, as a convenient and

pain-free

alternative to prandial insulin injections, could encourage insulin therapy

among those patients who presently avoid injections. We look forward to our

collaboration with Generex to revolutionize the treatment of diabetes in

India. "

Generex Oral-lyn is Generex's flagship product, a proprietary oral

insulin spray that has been approved in India by the Central Drugs Standard

Control

Organization (CDSCO), Directorate General of Health Services, Government of

India, for importation, commercial marketing and sale for the treatment of

Type 1 and Type 2 diabetes. Generex Oral-lyn is the first non-injectable

buccal insulin approved in India. Unlike inhaled insulin products, buccally

absorbed Generex Oral-lyn does not have pulmonary side effects. Generex

Oral-lyn is safely and efficiently delivered without pain via the

Company's

proprietary RapidMist device, which looks like a simple asthma inhaler,

but provides complete absorption through the buccal mucosa (lining of the

mouth)

with no deposit in the lungs.

===========================

Dr. Bernstein's Secrets To Normal Blood Sugars. A five CD set containing

personal education straight from Dr. Bernstein himself. Audio and Video,

plus

hours of seminars, transcripts, and more. Learn more here.

http://www.diabetes911.net/secrets.php

Send to Friend

| Share |

Print |

Category |

Home

This article originally posted November 19, 2008 and appeared in

Issue 443

Past five issues:

Issue 443 |

Issue 442 |

Issue 441 |

Issue 440 |

Have a comment?

Post it here.

Visit the NEW Diabetes In Control Blog.

Click Here!

There are no comments to this article at this time.

Be the first!

Sign In

new oral insulin

Recommended Posts

Guest guest

Link to comment

Share on other sites

Join the conversation

Activity